Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Piaopiao Li, Rahul Patel, Jingchuan Guo, Scott M. Vouri, Lizheng Shi, Vivian Fonseca & Hui Shao. (2021) The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010–2018. Current Medical Research and Opinion 37:11, pages 1875-1880.
Read now
Read now
Kazuki Orime & Yasuo Terauchi. (2020) Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 21:17, pages 2101-2114.
Read now
Read now
Kathiroli Sujithra, Subramani Srinivasan, Dhananjayan Indumathi & Veerasamy Vinothkumar. (2019) Allyl methyl sulfide, a garlic active component mitigates hyperglycemia by restoration of circulatory antioxidant status and attenuating glycoprotein components in streptozotocin-induced experimental rats. Toxicology Mechanisms and Methods 29:3, pages 165-176.
Read now
Read now
Pierre Delanaye & André J. Scheen. (2019) Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 20:3, pages 277-294.
Read now
Read now
Articles from other publishers (19)
Ignacio Rodríguez-Rodríguez, María Campo-Valera & José-Víctor Rodríguez. (2023) Forecasting glycaemia for type 1 diabetes mellitus patients by means of IoMT devices. Internet of Things 24, pages 100945.
Crossref
Crossref
Daryl J. Fediuk, Donal N. Gorman, Stephanie‐An Stoddard, Yizhong Zhang, Adam G. Ogden, Jennifer A. Winton & Aditi R. Saxena. (2023) Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes. The Journal of Clinical Pharmacology.
Crossref
Crossref
Ignacio Rodríguez-Rodríguez, José-Víctor Rodríguez & María Campo-Valera. (2023) Applications of the Internet of Medical Things to Type 1 Diabetes Mellitus. Electronics 12:3, pages 756.
Crossref
Crossref
John G. Rizk, Jui-Ting Hsiung, Yousif Arif, Leila Hashemi, Keiichi Sumida, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh & Elani Streja. (2023) Triglycerides and Renal Outcomes According to Albuminuria and in Consideration of Other Metabolic Syndrome Components in Diabetic US Veterans. American Journal of Nephrology 54:1-2, pages 14-24.
Crossref
Crossref
Li-Na Liao, Tsai-Chung Li, Chih-Ching Yeh, Chia-Ing Li, Chiu-Shong Liu, Chuan-Wei Yang, Ya-Fei Yang, Chih-Hsueh Lin, Fuu-Jen Tsai & Cheng-Chieh Lin. (2022) Risk prediction of nephropathy by integrating clinical and genetic information among adult patients with type 2 diabetes. Acta Diabetologica 60:3, pages 413-424.
Crossref
Crossref
Yinhua Ni, Liujie Zheng, Sujie Nan, Lehui Ke, Zhengwei Fu & Juan Jin. (2022) Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota. Acta Biochimica et Biophysica Sinica 54:10, pages 1406-1420.
Crossref
Crossref
Li-Li Tong & Sharon G. Adler. (2022) Diabetic kidney disease treatment: new perspectives. Kidney Research and Clinical Practice 41:Suppl 2, pages S63-S73.
Crossref
Crossref
Vanita R. Aroda, Robert Bauer, Erik Christiansen, Martin Haluzík, Klaus Kallenbach, Eduard Montanya, Julio Rosenstock & Juris J. Meier. (2022)
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the
PIONEER
phase 3 programme
. Diabetes, Obesity and Metabolism 24:7, pages 1338-1350.
Crossref
Crossref
Armand A. Krikorian & Angela Pauline P. Calimag. 2022. Diabetes and Kidney Disease. Diabetes and Kidney Disease
443
467
.
Haixia Chen & Ruilin Li. 2021. Structure and Health Effects of Natural Products on Diabetes Mellitus. Structure and Health Effects of Natural Products on Diabetes Mellitus
1
15
.
Alva O. Ferdinand, Marvellous A. Akinlotan, Timothy Callaghan, Samuel D. TowneJrJr & Jane N. Bolin. (2020)
Factors affecting the likelihood of a hospitalization following a
diabetes‐related
emergency department visit: A regional and
urban‐rural
analysis
. Journal of Diabetes 12:9, pages 686-696.
Crossref
Crossref
Mark E. Cooper, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Christoph Wanner, Sven Schnaidt, Douglas Clark & Odd Erik Johansen. (2020) Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial. Diabetes, Obesity and Metabolism 22:7, pages 1062-1073.
Crossref
Crossref
Aleksandra KuklaJennifer HillMassini MerzkaniAndrew BentallElizabeth C. LorenzWalter D. ParkMatthew D’CostaYogish C. KudvaMark D. StegallPankaj Shah. (2020) The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients. Transplantation Direct 6:2, pages e524.
Crossref
Crossref
Petar M. Seferović, Andrew J.S. Coats, Piotr Ponikowski, Gerasimos Filippatos, Martin Huelsmann, Pardeep S. Jhund, Marija M. Polovina, Michel Komajda, Jelena Seferović, Ibrahim Sari, Francesco Cosentino, Giuseppe Ambrosio, Marco Metra, Massimo Piepoli, Ovidiu Chioncel, Lars H. Lund, Thomas Thum, Rudolf A. De Boer, Wilfried Mullens, Yuri Lopatin, Maurizio Volterrani, Loreena Hill, Johann Bauersachs, Alexander Lyon, Mark C. Petrie, Stefan Anker & Giuseppe M.C. Rosano. (2020) European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure. European Journal of Heart Failure 22:2, pages 196-213.
Crossref
Crossref
Sanjay Kalra, Hasan Aydin, Manisha Sahay, Sujoy Ghosh, Sundeep Ruder, Mangesh Tiwaskar, Gary Kilov, Kamal Kishor, Tiny Nair, Vikas Makkar, Ambika Gopalakrishnan Unnikrishnan, Dinesh Dhanda, Nikhil Gupta, Bharath Srinivasan & Amit Kumar. (2020) Cardiorenal Syndrome in Type 2 Diabetes Mellitus – Rational Use of Sodium–glucose Cotransporter-2 Inhibitors. European Endocrinology 16:2, pages 113.
Crossref
Crossref
Wei Liu, Jiangyi Yu, Ting Tian, Junjun Miao & Wenbin Shang. (2019) Meta‑analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy. Experimental and Therapeutic Medicine.
Crossref
Crossref
Mortaza F. Hassanabad & Zahra F.H. Abad. (2019) Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:3, pages 1893-1896.
Crossref
Crossref
A.J. Scheen. (2019) Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes & Metabolism 45:2, pages 110-121.
Crossref
Crossref
Ignacio Rodríguez-Rodríguez, José-Víctor Rodríguez & Miguel-Ángel Zamora-Izquierdo. (2018) Variables to Be Monitored via Biomedical Sensors for Complete Type 1 Diabetes Mellitus Management: An Extension of the “On-Board” Concept. Journal of Diabetes Research 2018, pages 1-14.
Crossref
Crossref